Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.74 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.72 |
| ▸ | F2 | P00734 | 2/20 | 0.72 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.72 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.72 |
| ▸ | PLAU | P00749 | 1/20 | 0.72 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 1/20 | 0.72 |
| ▸ | PLG | P00747 | 1/20 | 0.72 |
| ▸ | S100B | P04271 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | AOC1 | P19801 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522432 | 0.98 | PRMT1 (0.75) | PRSS1PRMT1F2ST14TMPRSS2 | |
| SCHEMBL14599520 | 0.98 | PRMT1 (0.75) | PRSS1PRMT1F2ST14TMPRSS2 | |
| Pentamidine SCHEMBL21462087 | 0.98 | PRMT1 (0.75) | PRSS1PRMT1F2ST14TMPRSS2 | |
| Hydrochloric Acid SCHEMBL5526299 | 0.97 | PRSS1 (0.76) | PRSS1PRMT1F2ST14TMPRSS2 | |
| SCHEMBL8407255 | 0.95 | PRSS1 (0.68) | PRSS1PRMT1F2ST14TMPRSS2 | |
| SCHEMBL7748657 | 0.95 | PRSS1 (0.71) | PRSS1PRMT1F2ST14TMPRSS2 | |
| Pentamidine SCHEMBL27820863 | 0.94 | PRMT1 (0.77) | PRSS1PRMT1F2ST14TMPRSS2 | |
| Hydrochloric Acid SCHEMBL8409943 | 0.93 | PRSS1 (0.69) | PRSS1PRMT1F2ST14TMPRSS2 | |
| SCHEMBL8410366 | 0.91 | PRSS1 (0.65) | PRSS1PRMT1F2ST14TMPRSS2 | |
| SCHEMBL12461746 | 0.90 | ITGB3 (0.70) | PRSS1PRMT1F2ST14TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | disclosed |
| US-20070099906-A1 | Combinations for the treatment of noeplastic disorders | COMBINATORX, INC. | 2007-05-03 | — | — | US | disclosed |
| EP-0725059-B1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMA (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6048854-A | ANTICOAGULANTS; ANTICANCER AGENT; WOUND HEALING AGENTS;BONE DISORDERS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0725059-A1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | PRSS1 2212/4885PRMT1 2584/4885F2 2085/4885 |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | PRSS1 1743/4885PRMT1 4691/4885F2 4843/4885 |
| US-20070099906-A1 | Combinations for the treatment of noeplastic disorders | NOP56, XPOT, NPM1 | PRSS1 4047/4885PRMT1 406/4885F2 2263/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | PRSS1 2775/4885PRMT1 2874/4885F2 1152/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | PRSS1 346/4885PRMT1 2596/4885F2 2448/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | PRSS1 2775/4885PRMT1 2874/4885F2 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.